Mumbai, Maharashtra, India, April 2025 — Anurag Mantri has been appointed as President (Senior Management Personnel) at Glenmark Pharmaceuticals, marking a strategic addition to the company’s global leadership team. Known for his deep financial expertise and value-creation mindset, Anurag will play a critical role in shaping Glenmark’s future direction, especially in areas of corporate finance, compliance, and business transformation.
Prior to joining Glenmark, Anurag served as Executive Director & Group CFO at Jindal Stainless, where he played a transformative role since 2016. His leadership was instrumental in driving enterprise value, global compliance, IPOs, M&A transactions, and strengthening financial governance. Pending final approvals by the Board and Committees, Anurag is also being considered for the additional role of Executive Director and Global Chief Financial Officer at Glenmark.
Anurag’s distinguished three-decade career spans across prestigious organizations. He began his journey with Larsen & Toubro, followed by leadership stints at HCLTech, SRF Limited, Cairn Energy PLC, ACME Group (Solar), and Schneider Electric Infrastructure Limited. His strategic contributions have ranged from global treasury, investor relations, and ERP integration to spearheading large equity and debt funding rounds, including India’s largest $2B IPO with Cairn. His experience across diverse sectors and geographies positions him strongly for his new role at Glenmark.
A qualified Chartered Accountant and a Commerce graduate from the University of Rajasthan, Anurag has consistently demonstrated excellence in financial stewardship, business transformation, and cross-functional leadership. His appointment is expected to further Glenmark’s mission to innovate, expand its global footprint, and drive sustainable growth in the healthcare sector.
Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives through innovation. Over the past four decades, Glenmark has grown from a generics-focused company to a major player in the global branded generics and specialty pharmaceutical markets, with operations in over 80 countries and 10 world-class manufacturing facilities across four continents. With strong therapeutic focus in dermatology, respiratory, and oncology, Glenmark has also consolidated its innovation capabilities under Ichnos Glenmark Innovation (IGI), aimed at driving breakthroughs in oncology and biologics. Sustainability and ESG are core to its operations, alongside impactful CSR efforts that have touched over three million lives.
Read Also : HR Is Not a Support Function—It’s the CEO’s Most Powerful Growth Engine
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
From Gatekeeping to Gateway Building: Transforming How Organisations Create Access
Leadership In Talent Management: A Powerful Driver for Economic Growth
